Petrović Vladimir, Vuković Vladimir, Patić Aleksandra, Marković Miloš, Ristić Mioljub
Department of Epidemiology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.
Institute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.
Vaccines (Basel). 2022 Dec 26;11(1):56. doi: 10.3390/vaccines11010056.
Many available SARS-CoV-2 vaccines demonstrated good humoral response, but studies directly comparing their immunogenicity in the general population are lacking. We evaluated the medium−term kinetics of anti-S SARS-CoV-2 antibodies (Abs) at one and six months after the second dose of BNT162b2, BBIBP-CorV, and Gam-COVID-Vac. Immunogenicity at six months was directly compared between BNT162b2, BBIBP-CorV, Gam-COVID-Vac, and ChAdOx1 nCoV-19. Participants ≥ 20 years old from Novi Sad, Serbia, without prior SARS-CoV-2 infection, were included. Anti S1/S2 IgG antibodies were measured using quantitative LIAISON SARS-CoV-2 assay. A total of 368 participants were included: 231 (62.77%) had sera collected at two time points. Two doses of BNT162b2 were received by 37.50% of participants, followed by BBIBP-CorV (22.01%), Gam-COVID-Vac (21.47%), and ChAdOx1 nCoV-19 (19.02%). Mean Ab levels at the 28th day and 6 months were 216.55 (SD = 105.73) AU/mL and 75.68 (SD = 57.30) for BNT162b2, 194.38 (SD = 140.24) and 90.53 (SD = 111.30) for Gam-COVID-Vac, and 72.74 (SD = 80.04) and 24.43 (SD = 38.43) for BBIBP-CorV group (p < 0.01, between two time points across all three groups), with a significant difference between women and men (p < 0.01, for both sexes). At the sixth month post-vaccination, the highest mean Ab level was detected in Gam-COVID-Vac group (91.28 AU/mL, SD = 95.96), followed by BNT162b2 (85.25 AU/mL, SD = 60.02), ChAdOx1 nCoV-19 (64.22 AU/mL, SD = 65.30), and BBIBP-CorV (25.26 AU/mL, SD = 36.92) (p < 0.01). Anti-spike IgG persistence was demonstrated six months post-vaccination with a significant decline in Ab levels. These results suggest a lower protection against SARS-CoV-2 over time. Our findings support the introduction of additional (booster) doses.
许多现有的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗都显示出良好的体液反应，但缺乏在普通人群中直接比较它们免疫原性的研究。我们评估了在接种第二剂BNT162b2、BBIBP-CorV和重组新冠疫苗（Gam-COVID-Vac）后1个月和6个月时抗SARS-CoV-2刺突蛋白抗体（Abs）的中期动力学。直接比较了BNT162b2、BBIBP-CorV、Gam-COVID-Vac和牛津-阿斯利康新冠疫苗（ChAdOx1 nCoV-19）在6个月时的免疫原性。纳入了来自塞尔维亚诺维萨德、年龄≥20岁、既往无SARS-CoV-2感染的参与者。使用定量化学发光免疫分析法检测抗S1/S2 IgG抗体。总共纳入了368名参与者：231名（62.77%）在两个时间点采集了血清。37.50%的参与者接种了两剂BNT162b2，其次是BBIBP-CorV（22.01%）、Gam-COVID-Vac（21.47%）和ChAdOx1 nCoV-19（19.02%）。BNT162b2组在第28天和6个月时的平均抗体水平分别为216.55（标准差=105.73）AU/mL和75.68（标准差=57.30），Gam-COVID-Vac组为194.38（标准差=140.24）和90.53（标准差=111.30），BBIBP-CorV组为72.74（标准差=80.04）和24.43（标准差=38.43）（所有三组两个时间点之间p<0.01），男性和女性之间存在显著差异（两性p<0.01）。在接种疫苗后第6个月，Gam-COVID-Vac组检测到的平均抗体水平最高（91.28 AU/mL，标准差=95.96），其次是BNT162b2（85.25 AU/mL，标准差=60.02）、ChAdOx1 nCoV-19（64.22 AU/mL，标准差=65.30）和BBIBP-CorV（25.26 AU/mL，标准差=36.92）（p<0.01）。接种疫苗6个月后显示出抗刺突蛋白IgG的持续性，但抗体水平显著下降。这些结果表明随着时间推移对SARS-CoV-2的保护作用降低。我们的研究结果支持引入额外（加强）剂量。
